|
Dual-action topical formulations for enhanced skin penetration and targeted dermal repair
Background
Dermatological and cosmetic treatments increasingly focus on targeted delivery of active compounds to the deeper skin layers to combat photoaging, oxidative damage, and carcinogenesis. However, the stratum corneum presents a formidable barrier to percutaneous absorption, limiting the efficacy of topically applied actives. Conventional...
|
|
High-dose dry powder inhaler for dual pulmonary and oral indomethacin delivery
Background
Dry powder inhalers (DPIs) offer a non-invasive and rapid route for drug delivery, particularly for medications requiring swift systemic action. This is especially relevant for poorly soluble drugs such as indomethacin, where oral administration is often limited by gastrointestinal degradation and adverse side effects. For indications...
|
|
Multilayered drug delivery implants for localized brain tumor therapy
Background
As treatment strategies evolve for brain tumors, especially post-surgical resection, localized therapy is emerging as a promising alternative to systemic drug delivery. The blood-brain barrier, along with the sensitive anatomy of the brain, makes it difficult to achieve effective therapeutic concentrations using traditional methods without...
|
|
Covalent ERK inhibitors for suppressing cancer
BI-78D3, a small molecule, covalently binds to ERK1/2’s D-recruitment site, disrupting ERK signaling crucial for cancer cell growth. This shows promise for treating ERK-dependent cancers, including those resistant to BRAF inhibitors.
This disrupts ERK signaling crucial for cell proliferation and survival, particularly in certain cancers like...
|
|
Advanced nanoparticle delivery system for targeted pulmonary administration of therapeutic nucleic acids
Lipid nanoparticles (LNPs) are designed for delivering RNA to lung tissues via inhalation. Composed of ionizable lipids, phospholipids, PEG-lipids, and cholesterol, they encapsulate RNA for therapeutic or immunological purposes, maintaining stability during nebulization.
Background
Gene therapy and editing hold significant promise for treating genetic...
|
|
Nanoparticle technology for sustained release of therapeutic agents
This invention describes lipid-based nanoparticles designed for encapsulating and slowly releasing therapeutic agents, such as siRNA, to treat diseases. These nanoparticles enhance drug delivery efficiency and minimize rapid release, improving treatment outcomes and reducing side effects.
Background
Chronic inflammation-related diseases, such as rheumatoid...
|
|
Nanodelivery systems for long-term controlled release of pharmaceuticals
This invention describes a nanodelivery system for controlled drug release using biocompatible materials. It features implantable or injectable devices with precise aperture control for zero-order kinetics, ensuring consistent therapeutic delivery over extended periods of time.
Background
Implantable drug delivery systems offer significant advantages...
|
|
Individualized intranasal delivery system for direct pharmaceutical administration to the brain
The technology involves a customizable nasal delivery device for precise administration of medications directly to the brain, bypassing traditional barriers. It uses imaging techniques for optimal placement, enhancing drug delivery efficiency and minimizing systemic side effects.
Background
Oral administration remains the predominant method for drug...
|
|
pH-sensitive hydrogel technology for enhanced oral delivery of high molecular weight therapeutic proteins
This invention describes a pH-sensitive hydrogel for oral delivery of therapeutic proteins like factor VIII or IX, used in hemophilia treatment. It protects proteins in the stomach and releases them in the intestine, enhancing bioavailability.
Background
Delivering therapeutic proteins orally presents significant challenges due to the body's natural...
|
|
pH-responsive hydrogel technology for enhanced oral delivery of therapeutic proteins
Improved hydrogel copolymers, made from itaconic acid and N-vinylpyrrolidone, enable oral delivery of therapeutic proteins by protecting them in the stomach and releasing them in the intestine. This enhances protein bioavailability and pharmacokinetics.
Background
Oral delivery of therapeutic proteins presents significant challenges due to the...
|
